ATE366936T1 - Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose - Google Patents

Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose

Info

Publication number
ATE366936T1
ATE366936T1 AT02713418T AT02713418T ATE366936T1 AT E366936 T1 ATE366936 T1 AT E366936T1 AT 02713418 T AT02713418 T AT 02713418T AT 02713418 T AT02713418 T AT 02713418T AT E366936 T1 ATE366936 T1 AT E366936T1
Authority
AT
Austria
Prior art keywords
methods
compositions
fibronectin fragments
cancer diagnosis
imaging
Prior art date
Application number
AT02713418T
Other languages
English (en)
Inventor
Donna Livant
Original Assignee
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Michigan filed Critical Univ Michigan
Application granted granted Critical
Publication of ATE366936T1 publication Critical patent/ATE366936T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02713418T 2001-01-18 2002-01-15 Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose ATE366936T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76549601A 2001-01-18 2001-01-18

Publications (1)

Publication Number Publication Date
ATE366936T1 true ATE366936T1 (de) 2007-08-15

Family

ID=25073705

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02713418T ATE366936T1 (de) 2001-01-18 2002-01-15 Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose

Country Status (5)

Country Link
EP (1) EP1388013B1 (de)
AT (1) ATE366936T1 (de)
CA (1) CA2435320C (de)
DE (1) DE60221115T2 (de)
WO (1) WO2002057786A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377763A1 (pl) 2002-11-25 2006-02-20 Attenuon, Llc. Peptydy, które hamują angiogenezę, migrację komórek, naciekanie komórkowe i proliferację komórkową oraz kompozycje zawierające te peptydy i ich zastosowania
CA2575675A1 (en) 2004-07-30 2006-03-09 Adeza Biomedical Corporation Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
EP2029779A4 (de) 2006-06-14 2010-01-20 Living Microsystems Inc Verwendung hoch paralleler snp-genotypisierung zur fötalen diagnose
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
US8372584B2 (en) 2006-06-14 2013-02-12 The General Hospital Corporation Rare cell analysis using sample splitting and DNA tags
EP2058662A1 (de) * 2007-10-17 2009-05-13 Koninklijke Philips Electronics N.V. Diagnose von Erkrankungen durch Messung des zellenvermittelten Abbaus der extrazellulären Matrix
SMT201700149T1 (it) 2008-09-20 2017-05-08 Univ Leland Stanford Junior Diagnosi non invasiva di aneuploidia fetale mediante sequenziamento
EP2182356A1 (de) * 2008-11-04 2010-05-05 Koninklijke Philips Electronics N.V. Verwendung von Serumproben zur Diagnose von Prostatakrebs durch Messen der Monozyt-Migration
KR101996705B1 (ko) * 2012-04-13 2019-07-04 프리딕션 바이오사이언시즈 에스. 에이. 에스. 세포 피브로넥틴의 빠른 시험법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894326A (en) * 1986-04-09 1990-01-16 Fred Hutchinson Cancer Research Center Monoclonal antibody defining oncofetal structure of fibronectin
US5840514A (en) * 1996-11-21 1998-11-24 The Regents Of The University Of Michigan Methods of testing cancer and anticancer drugs

Also Published As

Publication number Publication date
CA2435320A1 (en) 2002-07-25
DE60221115T2 (de) 2008-03-13
WO2002057786A2 (en) 2002-07-25
EP1388013B1 (de) 2007-07-11
CA2435320C (en) 2008-06-03
WO2002057786A3 (en) 2003-12-11
EP1388013A2 (de) 2004-02-11
DE60221115D1 (de) 2007-08-23

Similar Documents

Publication Publication Date Title
DK1918386T3 (da) Genekspressionsprofiler i biopsier af tumorvæv
EP2130926A3 (de) Phagen-Mikroarray-Profilerstellung der humoralen Antwort auf Erkrankungen
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2003042661A3 (en) Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
EP2230319A3 (de) Genexpressionsmarker für Brustkrebsprognose
ATE476908T1 (de) System und diagnoseverfahren zur optischen detektion von verdächtigen stellen einer gewebeprobe
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ATE478062T1 (de) Zusammensetzungen und verfahren zur in vivo abbildung von loeslichen beta-amyloid
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
ATE366936T1 (de) Zusammensetzungen und verfahren zur verwendung von fibronektin-fragmenten bei krebsdiagnose
TW200626899A (en) Frizzled proteins and detection and treatment of cancer
TW200626900A (en) Wnt proteins and detection and treatment of cancer
IL151448A0 (en) Proteins
DE60032784D1 (de) Markerproteine für prostatakrebs
WO2004104591A3 (en) Improvements to gamma delta t cell-mediated therapy
WO2004040312A3 (fr) Proceded de dosage du ngf pour le diagnostic in vitro du cancer du sein et utilisation en therapie
WO2003069553A3 (en) Method of image analysis
WO2007033167A3 (en) Compositions and methods for detecting and treating cancer
DE60113968D1 (de) Diagnose von brustkrebs unter verwendung von bcmp-7 als marker
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
NO20004250D0 (no) Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet
EA200802356A1 (ru) Способ выявления и диагностики злокачественного новообразования, включающий праймеры и зонды для специфичного выявления маркера mage-a3
EP1619950A4 (de) Prognose, diagnose und behandlung von mit knochenmarkstammzellen assoziiertem krebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties